ArticleTrends in molecular medicine2016
Introducing a New Dimension to Molecular Disease Classifications.
Article in Trends in molecular medicine, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Rare variants in non-coding regulatory regions of the genome that affect gene expression in systemic lupus erythematosus.Scientific reports · 2019Trial
- Serum untargeted metabolomics alterations in systemic lupus erythematosus patients with elevated serum ferritin.Scientific reports · 2025Article
- Longitudinal association of type 1 interferon-induced chemokines with disease activity in systemic lupus erythematosus.Scientific reports · 2018Article
- Pathogenesis of Human Systemic Lupus Erythematosus: A Cellular Perspective.Trends in molecular medicine · 2017Review
- Understanding Human Autoimmunity and Autoinflammation Through Transcriptomics.Annual review of immunology · 2017Review
- Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity.Nature reviews. Drug discovery · 2017Review
- Finger stick blood collection for gene expression profiling and storage of tempus blood RNA tubes.F1000Research · 2016Article
Corrections and comments
- Comment on
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic lupus erythematosus (SLE) is an autoimmune disease presenting with a wide range of clinical manifestations. A recent study in Cell has uncovered distinct molecular classes of pediatric SLE patients. The approach employed is remarkable in that it may enable alignment of molecular classifications of disease with the development and selection of novel treatment modalities.
Indexed as
Identifiers
27161597What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.